In Brief: Neoprobe
This article was originally published in The Gray Sheet
Executive Summary
Reduces workforce by 20% and intends to reduce operating expenditures in 1998 by approximately 30% as part of a "strategic assessment and restructuring" announced Feb. 18. The Dublin, Ohio firm plans to refocus resources on its three key business goals: commercializing its RIGScan CR49 system for surgical detection of metastatic colorectal cancer; maximizing instrument sales for gamma guided surgery applications and developing activated cellular therapy products for cancer and viral diseases. The company, which anticipates an operating loss of about $12 mil. in fiscal 1998, hopes "to move the company toward profitability" in fiscal 1999. As part of the restructuring, David Bupp, president and chief operating officer, gains the title of CEO from John Ridihalgh, who remains chairman...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.